COMPANY PROFILE

EpiBiologics

Explore full profile

Expanding Protein Degradation to Membrane and Extracellular Targets

San Mateo, United StatesFounded 2022Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About EpiBiologics

EpiBiologics is a venture-backed biotechnology startup that operates in the field of targeted therapies. The company's primary focus is on the development of therapies that degrade disease-driving membrane and extracellular proteins. These proteins are often the underlying cause of various disorders, many of which currently lack effective treatment options.

Read full description

The company's proprietary EpiTAC platform is at the heart of its operations. This platform enables the creation of first-in-class and best-in-class targeted therapies. The company's approach has potential applications against a broad range of disorders, making it a versatile player in the biotech market.

EpiBiologics serves clients in the healthcare and pharmaceutical industries, particularly those seeking innovative solutions for hard-to-treat diseases. The company's business model revolves around the research, development, and commercialization of its targeted therapies. Revenue is generated through partnerships with other biotech and pharmaceutical companies, licensing agreements, and potentially, the sale of its therapies once they have received regulatory approval.

The company is also committed to building a strong team of scientists specializing in protein science and translational biology. This focus on human capital indicates a long-term strategy aimed at maintaining a competitive edge in the rapidly evolving biotech industry.

In summary, EpiBiologics is a promising biotech startup with a unique approach to treating diseases by targeting and degrading disease-driving proteins. Its proprietary technology and strong team of scientists position it well for future growth in the biotech industry.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: San Mateo, United States
Employees: 50
Open positions: None listed
Dealroom signal: 87.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Jan 2026	$107M	$428M	Polaris Partners · Vivo Capital · Samsara BioCapital · Mission BioCapital	↗
SERIES AOther financing	Jul 2023	$23M	$250M	GV · Polaris Partners · Vivo Capital · Digitalis Ventures	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

EpiBiologics website traffic

Latest recorded traffic for EpiBiologics is 2.5K monthly website visits, down 16.7% over the last three months. EpiBiologics's team grew 19% over the past year.

Latest monthly visits2.5K 3-month web change-16.7% 1-year team growth+19%

Monthly website visitsMar 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Mass Spec Scientist (contractor) - Large Molecule Characterization1900, Alameda de las Pulgas, San Mateo, San Mateo County, California, 94403, United States · Other · Aug 5, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CTCyclone TherapeuticsA preclinical-stage drug discovery company that focuses on improving protein quality control by modulating translation	San Diego, United States	Operational	1	$800K	$3.2M
DBDiffuse BioWe're building push-button software for drug design, driven by breakthroughs in generative AI	San Francisco, United States	Operational
DPDISCO PharmaceuticalsBiotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds	Cologne, Germany	Operational
WMWild MicrobesBiotech & Life Sciences	Cambridge, United States	Operational
MOMoleculeMindA leading AI protein design platform company	Haidian, China	Operational
MAMatchpointDesigning a new era of precision covalent medicines informed by breakthroughs in ultradeep chemoproteomics and machine learning	Boston, United States	Operational
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational